Side-by-side · Research reference

GHK-CuvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED8/47 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

GHK-Cu

Tripeptide · Skin / Hair / Wound Healing

1–2 mgSQ dosePickart 2018

HumanMechanisticPickart 2018 Zink 2003

HoursHalf-life

SQ or topical · Local · Daily or 2-3×/week

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

GHK-Cu

Vesugen

Primary target

Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018 Zink 2003

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Replaces declining endogenous levels

Not applicable — does not operate via hormone axis

Origin

Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

GHK-Cu

Vesugen

Standard SQ dose

1–2 mg / dayPickart 2018

Anecdotal injectable range; topical creams use 0.1–2% solutions.

—

Topical concentration

0.1–2.0% in serum / cream

—

Frequency

Daily or 2–3× per week (SQ)

Not specified in available literature

Lower / starter dose

0.5 mg / day SQ

—

Evidence basis

Human-mechanistic + topical clinical studiesPickart 2018

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

8–12 weeks for visible skin / hair effect

Case series report treatment courses in elderly arterial insufficiency

Reconstitution

Bacteriostatic water; light-protected

—

Timing

No specific time; evening preferred for topicals

—

Half-life

Hours (estimated; rapid tissue uptake)

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

04Side Effects & Safety

Parameter

GHK-Cu

Vesugen

Injection site reaction

Erythema, mild pruritus (common)

—

Topical irritation

Mild redness, transient stinging

—

Copper accumulation

Theoretical with very high chronic doses

—

Allergic reaction

Rare hypersensitivity to copper

—

Pregnancy / OB

Avoid topical and SQ — insufficient data

—

Wilson disease

Contraindicated

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

GHK-Cu

·Wilson disease (copper-overload disorder)
·Pregnancy / breastfeeding
·Known copper hypersensitivity

Vesugen

—

Relative Contraindications

GHK-Cu

·Hemochromatosis (copper-iron crosstalk theoretical)
·Concurrent copper-chelator therapy

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

GHK-Cu

Vesugen

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Anytime; evening preferred. Topical: apply to clean dry skin.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Needle

30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.

—

06Stack Synergy

GHK-Cu

+ BPC-157

Moderate

View BPC-157 →

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu: 1–2 mg SQ · daily near wound
BPC-157: 250–500 mcg SQ · daily near wound
Primary benefit: Combined ECM rebuilding + angiogenesis for tissue repair

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)